

CURRICULUM VITAE

Name: **Dr. GAURAV RAJ DWIVEDI**
Designation: **Scientist- E (Talent Search Scientist)**
Department: **Microbiology**
Institute: **ICMR-Regional Medical Research Centre, Gorakhpur, Uttar Pradesh-273013.**
Date of Birth: **30/12/1980**

Qualifications

- **Doctoral (Microbiology). 2013.** CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India & Dr. R. M. L. Avadh University, Faizabad (U.P.), India.
- **Master (Microbiology). 2001.** Dr. R. M. L. Avadh University, Faizabad (U.P.), India.

Awards/ Honours

- Talent Search Scheme (ICMR-2017)
- Best Poster Award 2015. AMTSG-2015 at BBA University.
- Best Poster Award 2014. MAPSI-LAMP at Biotech Park & CSIR-CIMAP.
- SERB-Young Scientist-2014
- CSIR-Senior Research Fellowship 2009
- Graduate aptitude test in engineering (GATE-2003) with 93.20 percentile (2003).
- CSIR-NET-LS (Dec. 2003)

Positions (Experience)

Designation	University/ Institution	From (Month/Year)	To (Month/Year)
Scientist-E	ICMR-Regional Medical Research Centre, Gorakhpur India	1 January 2026	Present
Scientist-D	ICMR-Regional Medical Research Centre, Gorakhpur India	September 2021	December 2025
Scientist-C	ICMR-Regional Medical Research Centre, Gorakhpur India	June 2019	August 2021
Scientist-C	ICMR-Regional Medical Research Centre Bhubaneswar Odisha.	July 2017	May 2019
SERB-Young Scientist	B.B.A. University, Lucknow (U. P.) & CSIR- Central Institute of Medicinal and Aromatic Plants, Lucknow India	April 2015	June 2017
Assistant Professor	B.B.A. University, Lucknow (U. P.)	September 2014	March 2015
Research Scientist	BioBrainz Life sciences, Lucknow	January 2014	August 2014
Project Fellow	CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow India	January 2013	January 2014
CSIR-Senior Research Fellow	CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow India	August 2009	August 2012
Junior Research Fellow	CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow India	September 2004	July 2009

Publications (Numbers only)

Research Papers: **90** with impact factor **>400 (Clarivate analytics 2025)**, Book Chapters: **07**, Popular articles: **03**, Editor: **01** *Current Topic in Medicinal Chemistry*

Bibliographical details of Relevant publications

1. Bhardwaj P, Joshi HS, Dwivedi GR. *Ochrobactrum intermedium*. Trends Microbiol. 2026 S0966-842X(25)00377-4. doi: 10.1016/j.tim.2025.12.014. Epub ahead of print. PMID: 41690833. **Impact factor: 14.99.**
2. Behera SP, Bhardwaj P, Srivastava P, Tiwari S, Kumar M, Mishra N, Kumar R, Singh N, Singh R, Joshi HS, Dwivedi GR. A rare and first report of *Ochrobactrum intermedium* co-infection in coxsackievirus-A24-infected acute hemorrhagic conjunctivitis patients. Folia Microbiol (Praha). 2025 Aug;70(4):891-897. doi: 10.1007/s12223-025-01300-5. Epub 2025 Jul 14. PMID: 40658356.
3. Sapkal G, Kant R, **Dwivedi G**, Sahay RR, Yadav PD, Deshpande GR, Singh R, Nyayanit DA, Patil DY, Shete-Aich AM, Zaman K, Chaudhari AK, Gupta N, Panda S, Abraham P, Bhargava B. Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine. J Travel Med. 2022, 29(3): taac033. **Impact factor: 39.49.**
4. Sapkal G, Kant R, **Dwivedi G**, Sahay RR, Yadav PD, Deshpande GR, Singh R, Nyayanit DA, Patil DY, Shete-Aich AM, Zaman K, Chaudhari AK, Gupta N, Panda S, Abraham P, Bhargava B. Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine. J Travel Med. 2022, 29(3): taac033. **Impact factor: 39.49.**
5. Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Santhosh Kumar M, Selvaraju S, Rade K, Kumar CPG, Sabarinathan R, Asthana S, Balachandar R, Bangar SD, Bansal AK, Bhat J, Chakraborty D, Chopra V, Das D, Devi KR, **Dwivedi GR**, Jain A, Khan SMS, Kumar MS, Laxmaiah A, Madhukar M, Mahapatra A, Ramesh T, Rangaraju C, Turuk J, Yadav S, Bhargava B; ICMR serosurveillance group. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study. PLoS Med. 2021;18(12): e1003877. **Impact factor: 15.76.**
6. **Dwivedi GR***, Rai R, Pratap R, Singh K, Pati S, Sahu SN, Kant R, Darokar MP, Yadav DK. Drug resistance reversal potential of multifunctional thieno[3,2-c]pyran via potentiation of antibiotics in MDR *P. aeruginosa*. Biomed Pharmacother. 2021 142:112084. **Impact factor 7.56.**
7. Murhekar M, Bhatnagar T, Selvaraju S, Saravanakumar V, Jeromie WV, Sah N, Kumar SM, Rade K, Shah N, Sabarinathan R, Asthana S, Balachandar R, Bangar SD, Bansal AK, Bhat J, Rangaraju C, Chopra V, Das D, Dev AK, Devi RK, **Dwivedi GR et al.** SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household Sero-survey. Lancet Glob Health, 2021, S2214-109X (20)30544-1. doi: 10.1016/S2214-109X (20)30544-1. **Impact factor 21.56.**
8. **Dwivedi GR***, Khwaja S, Negi AS, Panda SS, Swaroop AS, Pati S, Gupta AC, Bawankule DU, Chanda D, Kant R, Darokar MP. Design, synthesis and drug resistance reversal potential of novel curcumin mimics Van D Synergy potential of curcumin mimics. Bioorganic Chem, 2021, 106, 104454 Doi: <https://doi.org/10.1016/j.bioorg.2020.104454>, **Impact factor- 4.831.**
9. **Dwivedi GR***, Guest Editor of thematic issue “Role of botanicals/endophytic compounds in modulation of multidrug transporters” *Curr Top Med Chem*, 2019, 19(10): 753. **Impact factor- 3.442.**
10. **Dwivedi GR**, Maurya A, Yadav DK, Tewari N, Pal A, Khan F, Srivastava SK, Darokar MP. Comparative Drug Resistance Reversal Potential of Natural Glycosides: Potential of Synergy Niaziridin & Niazirin, *Curr Top Med Chem*. 2019, 19(10): 847-860. doi: 10.2174/1568026619666190412120008. **Impact factor-**

3.442.

11. Dwivedi GR, Maurya A, Yadav DK, Singh V, Khan F, Srivastava SK, Darokar MP. Synergy of clavine alkaloid ‘chanoclavine’ with tetracycline against multi drug resistant *E. coli*. *J Biomol Struct Dyn*, 2019 37(5):1307-1325. Impact factor- 3.310.

12. Dwivedi GR, Tewari N, Singh A, Kumar A, Roy S, Negi AS, Pal A, Sharma A, Darokar MP. Gallic acid based indanone derivative interacts synergistically with tetracycline by inhibiting efflux pump in multidrug resistant *E. coli*. *Appl Microbiol Biotechnol*, 2016, 100: 2311-2325. Impact factor- 3.831.

**Corresponding author*

List of Research Projects undertaken

Title of Project	Source of Funds	PI/Co-PI	Budget (Rs)	Duration
<i>Investigation of species/genotype diversity and drug resistance of plasmodium in malaria cases from selected district of U.P. by targeted deep amplicon sequencing</i>	ICMR	PI	2.64 Crore	2025-2028
<i>Integrated sentinel serosurveillance for communicable diseases using multiplex serological assays in India</i>	ICMR	PI	2.4 Crore	2024-2026
<i>Pan India surveillance for respiratory viruses through DHR-ICMR VRDL Network</i>	DHR-ICMR	PI	735480	2024-2026
<i>Strengthening genomic surveillance for vector borne diseases endemic in India</i>	Bill & Milinda Gates	PI	1212000	2024-2026
<i>Monitoring resistance to Doxycycline & Azithromycin in AFI/AES cases with scrub typhus in eastern Uttar Pradesh</i>	ICMR	PI	1.59 Crore	2024-27
<i>Seroprevalence, risk factors and molecular epidemiology of viral hepatitis: A population-based survey in Tharu tribes of eastern Uttar Pradesh</i>	ICMR	PI	1.79	2024-27
<i>Development of a sustainable network of laboratories in India for identification, monitoring and research on virus and bacteria causing acute encephalitis syndrome and other novel pathogens through capacity building in advanced biomedical technologies</i>	PM-ABHIM	PI	24.5 Crore	2023-25
<i>Immune response to precautionary third dose of COVISHIELD/COVAXIN among healthy adult population: an ICMR Cohort study, India</i>	ICMR	PI	4.61 Crore	2021-2024
<i>Determination of resistance frequency and intensity among field populations of malaria vectors to public health insecticides in use in endemic States of India”</i>	ICMR	PI	18Lac	2023-25
<i>DLSS: Sentinel Surveillance for tuberculosis burden in India 2022-2024” under the Project Strengthening the monitoring of Tuberculosis Elimination in India</i>	Global Fund	PI	1.5 Crore	2024-2025
<i>A Demonstration Project for reduction of Tuberculosis in India- A Multicentric Study</i>	ICMR	PI	1.74Crore	2023-2025
<i>Evaluation of immunogenicity and protective efficacy after vaccine interchangeability in a selected population of Eastern UP</i>	ICMR	PI	84,40,000 /-	2021-2023

<i>Setting up of Nationwide Network of Laboratories for Managing Epidemics and National Calamities” to the Regional Medical Research Center, Gorakhpur, State Level VRDL, through ICMR</i>	DHR	PI	18 Crore	2021-2026
<i>Population-based serosurvey to estimate prevalence of SARS-CoV-2 antibodies in India: Fourth survey, June - July 2021</i>	ICMR	PI	20Lac	June July 2021
<i>National Survey for State Wise Prevalence of Microbiologically Confirmed Pulmonary Tuberculosis in India”.</i>	ICMR, WHO	PI	Budget: 1.58 Crore.	2019-2021
<i>National Sero-surveillance for COVID-19</i>	ICMR intramural	PI	Budget: 10 Lac	May 2020
<i>Population-based serosurveillance for SARS-CoV-2 infection transmission in India: Second survey, August 2020</i>	ICMR intramural	PI	Budget: 10 Lac	August 2020
<i>Population-based serosurveillance for SARS-CoV-2 infection transmission in India: Third survey, December 2020</i>	ICMR intramural	PI	Budget: 10 Lac	December 2020
<i>Impact of COVID-19 on Maternal and Child health services in India</i>	ICMR, UNISEF	PI	Budget: 5 Lac	2020-2021
<i>National Environmental Health Profile</i>	MoEF, New Delhi	Co-PI	52,67000-/-	2018-2021
<i>In-vitro assessment of plant products as antiviral agents against Herpes viruses</i>	ICMR Intramural	PI	10,00000-/-	2018-2021
<i>In-silico identification of novel drug target(s) and OMICs studies to discover potent inhibitors against superbug Pseudomonas aeruginosa</i>	SERB, New Delhi	PI	32,30000-/-	2015-2018
<i>Development of efflux pump-based bioassay for high throughput screening of phytomolecules combating bacterial multidrug resistant infections</i>	CSIR, New Delhi	PI	8,37600	2009-2012